The companies will also collaborate in developing combination therapies of A167 with other agents for commercialization in their respective territories.
Harbour BioMed has entered into an exclusive strategic partnership with Kelun-Biotech to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.